Furthermore, treatment with ibrutinib has been illustrated to impair the immune response to influenza, hepatitis C and zoster vaccines in people with CLL.49,50 The effect of treatment upon immune response to both infections and vaccines may be a key consideration in the development of second-generation BTK inhibitors for MS.51 The gene discussed is BTK; the disease is myeloid sarcoma.